Pagibaximab
Pagibaximab
Pagibaximab (pronunciation: pah-gi-bax-i-mab) is a type of monoclonal antibody that was designed for the prevention of Staphylococcus aureus infections in newborn infants. It is a biopharmaceutical product that was developed by Biosynexus Incorporated and GlaxoSmithKline.
Etymology
The name "Pagibaximab" is derived from the International Nonproprietary Names (INN), where "mab" stands for monoclonal antibody, "xi" indicates that it is a chimeric antibody, "ba" refers to bacterial targets, and "gi" is a random infix.
Mechanism of Action
Pagibaximab works by binding to the lipoteichoic acid (LTA) on the cell wall of Staphylococcus aureus, thereby preventing the bacteria from adhering to the host cells and causing an infection.
Clinical Trials
Pagibaximab has undergone Phase II clinical trials for the prevention of Staphylococcus aureus infections in newborns. However, it has not yet been approved by the Food and Drug Administration (FDA) for this indication.
Related Terms
- Monoclonal Antibody
- Staphylococcus aureus
- Lipoteichoic acid
- Biopharmaceutical
- Clinical trial
- Food and Drug Administration
External links
- Medical encyclopedia article on Pagibaximab
- Wikipedia's article - Pagibaximab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski